The Global PulmonaryDrugs Market, by Drug Class (Inhaled Corticosteroids, Long Acting Beta-2Agonists, Antihistamines, Vasodilators, and Others), by Application (Asthma& COPD, Allergic Rhinitis, Pulmonary Arterial Hypertension, CysticFibrosis, and Others), by Distribution Channel (Hospital Pharmacies, RetailPharmacies, and e-Commerce), and by Region (North America, Latin America,Europe, Asia Pacific, the Middle East, and Africa) was valued at US$ 28,064.5million in 2016 and is projected to exhibit a CAGR of 8.1% over the forecastperiod (2017 – 2025).
The pulmonary drugs market isexpected to gain significant traction with patent expiry of branded drugs,which is expected to generate opportunities for the market players and robustnumber of drug candidates in the pipeline as a result of extensive R&D.
Increasing prevalence ofrespiratory diseases is expected to propel growth of the market Increasingprevalence of chronic obstructive pulmonary diseases and other respiratorydiseases across the world is one of the leading causes of death and disability.Thus, the prevention, treatment, and control of these diseases is one of thetop priorities for governments and players in the healthcare sector. Accordingto the Forum of International Respiratory Societies, in 2016, around 65 millionpeople were suffering from chronic obstructive pulmonary disease worldwide,leading to 3 million deaths. Moreover, around 334 million people suffered fromasthma, which is the most common chronic respiratory condition among childrenas well as adults. A wide range of conditions are included within the ambit ofpulmonary diseases that include pneumonia, allergic rhinitis, pulmonaryhypertension, and others that are responsible for creating a giant economicburden on the healthcare sectors of most of nations. Pulmonary drugs arefocused towards providing medications for all these types of diseases leadingto expected market growth in near future. According to the World HealthOrganization, 2017, Chronic Obstructive Pulmonary Diseases (COPD) isresponsible for about 5% of the total deaths worldwide in 2015.
* The sample copy includes: Report Summary, Table ofContents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/1285
Furthermore, according to theOffice of Disease Prevention and Health Promotion 2014, 25 million patients inthe U.S. had asthma that led to an estimated annual expenditure for asthmaturning around to US$ 20.7 billion. Thus, the constant rise in the number patientssuffering with respiratory diseases are expected to surge the market growthover the forecast period.
Browse 50 Market Data Tables and38 Figures spread through 304 Pages and in-depth TOC on “Pulmonary Drugs Market”-Global Forecast to 2025.
The major manufacturers arefocused towards development of new and innovative products with extensiveR&D on pulmonary drugs. For instance, in 2017, Sanofi SA completed thephase II clinical trials in April 2017 of new drug Dupilumab in association withRegeneron Pharmaceuticals. The drug is indicated for the treatment ofuncontrolled asthma in children and is expected to complete its clinical trialstudies in January, 2021. Moreover, in 2017, Circassia Pharmaceuticalscompleted Phase IV clinical trials of Tudorza with a collaborative agreementbetween Circassia and AstraZeneca Plc. for the treatment of COPD. The keyplayers adopt the strategies of mergers, definitive agreements, andacquisitions to expand the respiratory drugs product portfolio, thereby increasingmarket share. For instance, in 2015, AstraZeneca Plc entered into a definitiveagreement with Takeda Pharmaceutical Company Limited, under which AstraZenecaacquired the core respiratory business of Takeda to strengthen respiratorytherapeutic portfolio. Furthermore, in 2016, Mylan N.V. acquired MedaPharmaceuticals to enhance geographic reach with significant sales of productsworldwide, in which China, South East Asia, and Middle East were the major regionaltargets for the company.
Browse ResearchReport: https://www.coherentmarketinsights.com/market-insight/pulmonary-drugs-market-1285
Key Takeaways of the PulmonaryDrugs Market:
The global pulmonary drugs marketis expected to exhibit a CAGR of 8.1% over the forecast period, owing to thepresence of high potential market and increasing prevalence of chronicrespiratory diseases in Asia Pacific, Latin America, the Middle East, andAfrica
Among drug class, inhaledcorticosteroids segment holds a dominant position attributed to the advantagesoffered by the drugs that include lower concentration of drug delivery into thepatient’s system allowing even distribution as well as lower risk of sideeffects that are usually exhibited by oral steroid consumption
Among application, asthma andCOPD segment holds a dominant position in the pulmonary drugs market, owing tothe rising incidence of the condition worldwide.
Some of the major playersoperating in the global pulmonary drugs market include Sanofi SA, MedaPharmaceuticals, Circassia Pharmaceuticals Plc., AstraZenca Plc.,GlaxoSmithKline Plc., Mallinckrodt Pharmaceuticals Plc., Cheisi farmaceuticiS.p.A., Zambon Company S.p.A., Alaxia SAS, and Merck Sharp & Dohme Limited.
Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/1285
AboutCoherent Market Insights:
CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollar opportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S.Office:
Name: Mr. Shah
CoherentMarket Insights 1001 4th Ave,
# 3200Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN: +050-5539-1737
